Annovis Bio, Inc. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Annovis Bio, Inc. (ANVS) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $20.00 thousand for the 3-month period ending 2021-09-30, per its 10-Q filed 2022-11-08.
Discontinued
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2022-11-08
- Annovis Bio, Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2021-09-30 was $20.00K.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month |
|---|---|
| 2021-09-30 | $20.00K 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |